Browsing by Author "Celik, Zerrin"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cytogenetic Profile and Phenotypical and Reproductive Complaints in 39 Patients with Turner Syndrome: A Single Center Experience
    (2023) Kazanci, Ferah; Celik, Zerrin; https://orcid.org/0000-0001-9158-220X; A-1229-2015
    Background/Aim: Turner syndrome (TS) is a genetic failure that influence phenotypic girls who have full or incomplete monosomy of X chromosome with a variety of clinical signs. The purpose of this study was to estimate TS cases based on their cytogenetic findings and clinical implications. Material and methods:Thirty-nine cases diagnosed with TS were retrospectively analyzed between November 2006 and December 2019. These patients were identified among 505 people who had their karyotypes analyzed for different reasons, including primary amenorrhea (PA), premature ovarian insufficiency (POI), TS phenotype, and uterine agenesis (UA). Karyotype analysis was carried out using Giemsa staining in accordance with the standard method on peripheral blood and fluorescence in situ hybridization (FISH) was used when necessary. Results: The median age of TS cases were 15 years (ranging from 4 to 32). The distribution of reasons for admission was as follows: 61.5% TS phenotype, 25.6% PA, 10.3% POI, and 2.6% UA with horseshoe kidney. The frequency of cytogenetic finding was 38.5% pure monosomy X and 61.5 % mosaic [30.7% monosomy X with structural rearrangements, 18% with X chromosomal structural abnormalities, 7.7% with X aneuploidy and 5.1% with Y chromosomal structural abnormalities]. The most accepted reason for both pure and mosaic TS group was TS phenotype. Conclusion: TS develops when one sex chromosome is wholly or incompletely removed as well as structurally altered. Phenotype, fertility, and life quality may differ according to the variability of cytogenetic findings. Comprehensive cytogenetic analysis is required for the patients for medical follow-up and genetic counselling.
  • Thumbnail Image
    Item
    Epigallocatechin 3-gallate applications on HT-29 and MCF-7 cell lines and evaluation of tumor suppressor gene methylation
    (2015) Terzi, Yunus Kasim; Kaya, Ozge Ozer; Iseri, Ozlem Darcansoy; Celik, Zerrin; Sahin, Feride Iffet
    Epigallocatechin 3-gallate (EGCG) is an antitumor molecule and shows this activity by binding to the active center of a methyltransferase enzyme (DNMT1). The methylation of DNA sequences of tumor suppressor and DNA repair genes is observed in different stages of carcinogenesis. In this study, we analyzed the effect of EGCG on the methylation status of 25 tumor suppressor genes in cancer cell lines HT-29 and MCF-7. HT-29 and MCF-7 cells were incubated with 10 mu M, 20 mu M, and 50 mu M and 1 mu M, 5 mu M, and 10 mu M EGCG for 48 h, respectively. We found promoter hypermethylation of (1) CDH13, GATA5, and RAR beta genes in MCF-7 cell line and (2) RAR beta, ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 genes in HT-29 cell line. However, (3) after EGCG application, no changes in methylation status were detected in our samples. Our results suggest that methylation status of tumor suppressor genes did not change with different EGCG doses.